ProPhase Labs, Inc.

PRPH Healthcare Diagnostics & Research

In the quarter to June 2026, revenue fell 18.9%, EPS grew 80.0%, free cash flow grew 56.7% and total debt rose 19.4%, each against the same quarter a year earlier.

0.01 0.00 0.00%
Market cap
$1.2M
P/E
0.0×
Fwd P/E
−0.6×
Dividend yield
—
F-score
4/9
Altman Z
−3.59
Beneish M
−4.90
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— 4 4 3
ROE
(185.40%) (271.49%) (331.81%) (543.95%)
ROA
(52.95%) (23.96%) (44.22%) (45.53%)
ROIC
(220.98%) (122.44%) (203.72%) (387.30%)
Return on Tangible Assets
92.34% 30.78% 46.92% 42.01%
Average Days of Receivables
237.12 129.03 166.04 178.45
Free Cash Flow per Share
(2.54) (0.97) (0.46) (0.39)
Free Cash Flow
(10.55) (8.22) (5.63) (5.53)
Other line items

Show all line items

Columns are period end dates